SYVN1/HRD1抗体;SYVN1/HRD1 Antibody—艾普蒂 新品

+ +

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

•  

   

     Immunoprecipitate (IP) analysis using the Antibody at 1:50 dilution. (wb at 1:1K dilution)    

  
  

SYVN1 (Synoviolin), also known as HRD1 (HMG-CoA reductase degradation protein 1), is an E3 ubiquitin ligase central to the endoplasmic reticulum-associated degradation (ERAD) pathway. It plays a critical role in maintaining proteostasis by targeting misfolded or unassembled proteins in the ER for ubiquitination and subsequent proteasomal degradation. Dysregulation of SYVN1/HRD1 has been linked to various diseases, including neurodegenerative disorders (e.g., Alzheimer’s and Parkinson’s), cancer, and autoimmune conditions, due to its involvement in protein quality control and stress response pathways.

Antibodies targeting SYVN1/HRD1 are essential tools for studying its expression, localization, and function. These antibodies are widely used in techniques such as Western blotting, immunoprecipitation, and immunofluorescence to investigate SYVN1/HRD1’s interaction with substrates (e.g., amyloid precursor protein or tau) and its regulatory mechanisms. Specific antibodies often recognize conserved epitopes across species, facilitating cross-species research. Validation typically includes knockout cell lines or siRNA-mediated silencing to confirm specificity.

Research using SYVN1/HRD1 antibodies has revealed its dual roles in disease contexts: while it can promote cancer cell survival by degrading tumor suppressors, it also mitigates neurodegeneration by clearing toxic protein aggregates. Its interplay with ER stress sensors like IRE1α further highlights its importance in the unfolded protein response (UPR). Reliable antibodies are thus vital for advancing therapeutic strategies targeting ERAD pathways.